"You can't read a business journal without noticing hedge funds are becoming more active investors. The CEOs of Protein Design Labs, ImClone, and Nabi all resigned to satisfy certain of their shareholder groups. Advanced Medical Optics (amO) was not able to acquire Bausch and Lomb (BOL) in part because of the shareholder activity against the deal. What initiated this new attention from hedge funds and what are their goals? What impact will activists have on your company and how should you approach an activist shareholder who is building a position
in your stock? Please join this interactive panel discussion to explore the impact of activist shareholders on management, the financial community, and business operations."

Objective1:Hear from a variety of stakeholders who are experienced with shareholder activism.

Objective2:Learn the goals of activist investors and how to approach them.

Objective3:Seek greater insight into the financial communities' thoughts on activist shareholders.